FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL						
OMB Number: 3235-0287						
Estimated average burden						
hours per response: 0.						

1. Name and Address of Reporting Person* WINSTON ROY						2. Issuer Name and Ticker or Trading Symbol Pacira BioSciences, Inc. [PCRX]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O PACIRA BIOSCIENCES, INC.					00	3. Date of Earliest Transaction (Month/Day/Year) 06/06/2022									Officer (give title below) Chief Medical			Other (specify below)		
5401 WEST KENNEDY BOULEVARD, SUITE 890 (Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)					
TAMPA	F	L	33609		_									X		•		rting Persor One Repor		
(City)	(5	State)	(Zip)							. 5:		·								
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				action	ion 2A. Deeme Execution		d Date,	3. 4. Se		sposed of, or Benefic 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amour		s Illy	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	: Direct r Indirect	7. Nature of Indirect Beneficial Ownership		
							, (,		Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common	Stock			06/06	5/2022	2			S		2,099(1)	D	\$61.	374	44,	357		D		
Common Stock 0			06/06	5/2022)22		M ⁽²⁾		6,250	A	\$34.	\$ 34.375 50		50,607		D				
Common	Common Stock 06/0		06/06	5/2022	2		S ⁽²⁾		2,535	D	\$ 60 .	\$60.55 ⁽³⁾ 48		18,072		D				
Common	ommon Stock 06/		06/06	5/2022	2			S ⁽²⁾		2,300	D	\$61 .	\$61.59 ⁽⁴⁾ 45,		,772		D			
Common	Stock			06/06	5/2022	2			S ⁽²⁾		1,300	D	\$62.	43(5)	44,	472		D		
Common	Stock			06/06	5/2022	2			S ⁽²⁾		115	D	\$63	.4(6)	44,	44,357		D		
Common	Stock			06/06	5/2022	2			S ⁽²⁾		3,533	D	\$60.	55(7)	40,824		4 D			
Common	Stock			06/06	5/2022	2			S ⁽²⁾		3,650	D	\$61 .	59 ⁽⁸⁾	37,	,174		D		
Common	Stock			06/06	5/2022	2			S ⁽²⁾		1,891	D	\$62.	48(9)	35,283		3 D			
Common	Stock			06/06	5/2022	2			S ⁽²⁾		123	D	\$63.6	59(10)	35,160			D		
Common	Stock			06/08	3/2022	2			A		9,900(11)	A	\$0.	00	45,	060		D		
			Table II								posed of, convertib				wned					
Derivative C Security (Instr. 3) P	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,	Code (Ins				6. Date Exe Expiration I (Month/Day			7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)			Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transacti	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershi ct (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amor or Numl of Share	ber	- Iransac (Instr. 4					
Stock Option (Right to	\$34.375	06/06/2022						6,250	(1	2)	05/02/2028	Common	6,2:	50	\$0.00	\$0.00 0		D		

Explanation of Responses:

\$59.39

06/08/2022

Stock Option

Buy)

(Right to

- 1. Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
- 2. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange

(13)

06/08/2032

24,800

Stock

\$0.00

24,800

D

- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$60.23 to \$61.22, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 3 through 10.
- 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$61.23 to \$62.17, inclusive.

24,800

- 5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$62.23 to \$62.78, inclusive.
- 6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$63.29 to \$64.14, inclusive.
- 7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$60.220 to \$61.215, inclusive.
- 8. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$61.22 to \$62.18, inclusive.
- 9. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$62.200 to \$62.935, inclusive.
- 10. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$63.60 to \$64.06, inclusive.
- 11. Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. 12. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the
- subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.
- 13. The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the

subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Remarks:

/s/ Kristen Williams, Attorneyin-Fact

06/08/2022

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

 $Note: File \ three \ copies \ of \ this \ Form, \ one \ of \ which \ must \ be \ manually \ signed. \ If \ space \ is \ insufficient, \ see \ Instruction \ 6 \ for \ procedure.$

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.